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Abstract
Vascular endothelial growth factor (VEGF) is increasingly recognized as a perinatal regulator of lung
maturation and surfactant protein expression. Preterm and young infants are at increased risk for pulmonary
immaturity characterized by insufficient surfactant production as well as increased risk for severe
manifestations of respiratory syncytial virus (RSV) infection. Innate immune components including
surfactant proteins A and D, and β-defensins have putative antimicrobial activity against pulmonary pathogens
including RSV. Our hypothesis was that recombinant human VEGF (rhVEGF) pretreatment therapy would
decrease RSV disease in the perinatal lamb RSV model. Newborn lambs were pretreated with rhVEGF,
betamethasone, or saline and then inoculated with bovine RSV or sterile medium. Tissues were collected 5 d
postinoculation, corresponding to the initiation of severe lesions and peak viral replication. In RSV-infected
lambs, rhVEGF therapy increased the mean daily body temperature, decreased airway neutrophil exudate, and
reduced RSV replication compared with betamethasone or saline pretreatment. Furthermore, rhVEGF
therapy significantly mitigated the RSV-induced increase in surfactant protein A mRNA expression and
decrease in surfactant protein D mRNA expression. In control (non-RSV-infected) lambs, pretreatment with
rhVEGF increased sheep β-defensin-1 (SBD1) mRNA expression, but no alteration in surfactant proteins A
and D was detected. This novel study demonstrates that rhVEGF pretreatment mitigates RSV disease and, in
addition, rhVEGF regulation of innate immune genes is dependent on RSV infection status.
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ABSTRACT
Vascular endothelial growth factor (VEGF) is increasingly recognized as a perinatal regulator of
lung maturation and surfactant protein expression. Preterm and young infants are at increased risk
for pulmonary immaturity characterized by insufficient surfactant production as well as increased
risk for severe manifestations of respiratory syncytial virus (RSV) infection. Innate immune com-
ponents including surfactant proteins A and D, and -defensins have putative antimicrobial activ-
ity against pulmonary pathogens including RSV. Our hypothesis was that recombinant human
VEGF (rhVEGF) pretreatment therapy would decrease RSV disease in the perinatal lamb RSV
model. Newborn lambs were pretreated with rhVEGF, betamethasone, or saline and then inocu-
lated with bovine RSV or sterile medium. Tissues were collected 5 d postinoculation, correspond-
ing to the initiation of severe lesions and peak viral replication. In RSV-infected lambs, rhVEGF
therapy increased the mean daily body temperature, decreased airway neutrophil exudate, and re-
duced RSV replication compared with betamethasone or saline pretreatment. Furthermore, rhVEGF
therapy significantly mitigated the RSV-induced increase in surfactant protein A mRNA expression
and decrease in surfactant protein D mRNA expression. In control (non-RSV-infected) lambs, pre-
treatment with rhVEGF increased sheep -defensin-1 (SBD1) mRNA expression, but no alteration
in surfactant proteins A and D was detected. This novel study demonstrates that rhVEGF pre-
treatment mitigates RSV disease and, in addition, rhVEGF regulation of innate immune genes is
dependent on RSV infection status.
1Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, Ames, Iowa.
2National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, Iowa.
INTRODUCTION
RESPIRATORY SYNCYTIAL VIRUS (RSV) is an enveloped,negative sense, single-stranded RNA pneumovirus
that is a significant cause of seasonal respiratory disease
in humans (18). In healthy adults, RSV infection often
results in a self-limiting respiratory disease. Yet, certain
subpopulations including preterm and low birth weight
infants are at increased risk for severe manifestations of
RSV disease requiring hospitalization (24,32,40). RSV is
the leading cause of bronchiolitis in infants and during
the 1980s and into the mid-1990s annual RSV-associated
hospitalization in the United States was estimated to be
over 125,000 with nearly 500 deaths (29,35,36). Lesions
frequently associated with severe RSV disease include
necrotizing bronchiolitis (causing atelectasis, hyperinfla-
tion, and wheezing) and pneumonia (characterized radi-
ographically as interstitial infiltrates, alveolar filling, and
consolidation) (18). Bovine RSV infection in the perina-
tal lamb model is a viable model for study of the RSV
disease and innate immune response (20,25).
Preterm and young infants are also predisposed to de-
veloping respiratory distress syndrome (RDS), which is
associated with immature development of pulmonary sur-
factant (33). Glucocorticoid therapy, a promoter of lung
maturation that was originally developed using sheep
models, is conventionally used as a prophylactic treat-
ment for premature birth (5,31,39). Unfortunately, glu-
cocorticoid administration is also associated with poten-
tial short- to long-term adverse effects including
alterations in neurological and cognitive development
(21). The potential for adverse effects by glucocorticoids
makes the search for novel and safer surfactant regula-
tors a priority. Human airway epithelial explants treated
with vascular endothelial growth factor (VEGF) exhib-
ited proliferation with increased surfactant mRNA and
protein expression (6) and surfactant proteins A and D
have antiviral activity including opsonization and aggre-
gation of RSV, and activation of macrophages (16). Fur-
thermore, preterm mice treated with exogenous recom-
binant human VEGF (rhVEGF) had increased pulmonary
maturation and survival (8). VEGF therapy has been con-
strained by concerns about potential adverse effects. For
instance, transgenic mice with constitutive chronic ex-
pression of VEGF in respiratory epithelium had pul-
monary lesions including chronic hemorrhage and alve-
olar remodeling (22). In a sheep model, intrabronchial
deposition of exogenous rhVEGF induced a dose-depen-
dent recruitment of monocyte/macrophages into the lung,
causing gross and microscopic lesions (27). Although
safety concerns regarding VEGF therapy are legitimate,
studies of short-term and lower dose applications thus far
have reported minimal clinical complications (8,27).
The prospect of rhVEGF therapy in perinatal patients
at risk for RDS could have additional ramifications as
these same patients are at elevated risk for severe RSV
disease. Preterm infants have reduced surfactant protein
expression including surfactant proteins A and D, which
both have proven anti-RSV activity (15,17). Because
VEGF is suggested to induce lung maturation and sur-
factant protein expression, this putative increase in (an-
tiviral) surfactant proteins might prove useful as a ther-
apy to prevent severe RSV disease (6,8,15). The
hypothesis of this study was that rhVEGF pretreatment
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would diminish RSV disease in perinatal lambs. We com-
pared this novel RDS therapy with traditional gluco-
corticoid therapy (betamethasone) and sham (sterile
medium) treatment. In this study we characterize RSV
infection through clinical signs, lesions, morphometry,
and innate immune gene expression.
MATERIALS AND METHODS
Animals
Date-mated pregnant ewes were obtained from Labo-
ratory Animal Resources (Iowa State University, Ames,
IA), with all procedures approved by the Animal Care
and Use Committee. After natural parturition, neonatal
lambs (6–12 h old) were randomly pretreated with ster-
ile saline (20 mL, intratracheal injection), sterile saline
(20 mL, intratracheal) plus betamethasone (4.0 mg/kg,
intramuscular), or recombinant human vascular endothe-
lial growth factor (rhVEGF, 5 g/mL  20 mL, intra-
tracheal; Invitrogen, Carlsbad, CA) (Table 1). After 30
min for acclimation, the lambs were further divided into
two treatment groups receiving either sterile saline (20
mL, intratracheal) or bovine respiratory syncytial virus
(bovine RSV strain 375, 103 to 104 TCID50 [50% tissue
culture infective doses]/mL  20 mL, intratracheal).
Lambs were given daily antibiotic (ceftiofur, 2.2 mg/kg
per day, intramuscular) to prevent bacterial complications
(41). During the course of infection, lambs were moni-
tored for clinical signs including body temperature. From
our previous experience with this model of RSV disease,
severe lesion development and peak viral replication oc-
cur on day 5 of infection (23,25). Lambs were killed with
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TABLE 1. EXPERIMENTAL DESIGN FOR ASSESSING VEGF
PRETREATMENT IN PERINATAL RSV DISEASEa
Group Pretreatmentb Treatmentc
C/Media Sterile saline Sterile medium
V/Media VEGF Sterile medium
B/Media Betamethasone Sterile medium
C/RSV Sterile saline Bovine RSV
V/RSV VEGF Bovine RSV
B/RSV Betamethasone Bovine RSV
aLambs were monitored during infection for clinical signs
and tissues were collected on day 5 of infection to assess for le-
sions, morphometry, immunohistochemistry, and gene expres-
sion (RSV, SBD1, SP-A, and SP-D).
bIntratracheal injection (20 mL, sterile saline or VEGF [5
g/mL]) or intramuscular injection (betamethasone, 4 mg/kg)
was administered approximately 30 min before treatment.
cIntratracheal injection (20 mL) of sterile medium or RSV
(bovine RSV strain 375, 103 to 104 TCID50/mL, intratracheal).
sodium pentobarbital on day 5 of infection, and lungs
were examined for gross lesions. Tissue was collected bi-
laterally from the cranial and middle lobes. Tissues were
either snap frozen on dry ice for quantitative polymerase
chain reaction (qPCR) or positioned in cassettes and
placed in 10% neutral-buffered formalin (24–48 h) for
morphologic and immunohistochemical analysis.
RNA isolation
Total tissue RNA was isolated from whole lung tissue
(right middle lobe) for gene expression analysis by hy-
drolysis probe-based fluorogenic one-step real-time
qPCR. Briefly, lung tissue samples were weighed, placed
into 3 mL of TRIzol reagent (Invitrogen), and homoge-
nized. The homogenate was vortexed and nuclease-free
chloroform (200 L) was added to each sample, mixed,
and then microcentrifuged at 12,000  g for 10 min. Top
aqueous layers were transferred into 500 L of nuclease-
free 2-propanol (Fisher Chemical, Fairlawn, NJ), vor-
texed, allowed to sit and again microcentrifuged with sub-
sequent removal of the top aqueous layer. The remaining
pellet was washed (75% nuclease-free ethanol) and mi-
crocentrifuged, the final supernatant was removed, and
the remaining samples were allowed to air dry under a
fume hood. Each pellet was resuspended (nuclease-free
0.1 mM EDTA, pH 7.0), heated to 65°C for 5 min, and
stored at 4°C. RNA isolates were assessed at 1:50 dilu-
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tion for quantity and purity by spectrophotometry at 260
and 280 nm followed immediately by DNase treatment
with TURBO DNase (TURBO DNA-free kit; Ambion,
Austin, TX). For each sample, 80 L of each supernatant
RNA was recovered and diluted 1:10 with nuclease-free
water (Ambion), resulting in 800 L of each RNA iso-
late.
qPCR
qPCR was carried out as a one-step process as previ-
ously described in detail (14). Each of our final 25-L one-
step real-time qPCRs contained the following: 12.5 L of
one-step master mix (TaqMan one-step RT-PCR master
mix reagents kit; Applied Biosystems, Foster City, CA),
MultiScribe reverse transcriptase (RT, 0.25 U/L), RNase
inhibitor (0.4 U/L), optimal forward and reverse primer
and fluorogenic probe concentrations (Table 2), nuclease-
free water, and 6.5 L of each RNA sample/template
(14,16). Thermocycling conditions for all qPCRs were as
follows: 35 min at 48°C, 10 min at 95°C, and 50 cycles
of 15 s at 95°C and 1 min at 58°C. All plates were run in
duplicate on a GeneAmp 5700 sequence detection system
(Applied Biosystems) and all output data were processed
as custom Excel files (Microsoft, Redmond, WA). 
The Pfaffl equation (value  [(Etarget)Ct(control  treated)]/
[(Ehousekeeper)Ct(control  treated)]) was used for relative
quantitation based on target-specific fluorescent signals
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TABLE 2. PRIMERS AND PROBES FOR OVINE GENE EXPRESSION ASSESSED BY REAL-TIME qPCR
Target Primer
gene (concentration) Sequencea
SBD1 Fwd (1000 nM) 5-CCATAGGAATAAAGGCGTCTGTG
Rev (1000 nM) 5-CGCGACAGGTGCCAATCT
Probe (150 nM) 5-6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA
SP-A Fwd (500 nM) 5-TGACCCTTATGCTCCTCTGGAT
Rev (500 nM) 5-GGGCTTCCAAGACAAACTTCCT
Probe (50 nM) 5-6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA
SP-D Fwd (500 nM) 5-ACGTTCTGCAGCTGAGAAT
Rev (500 nM) 5-TCGGTCATGCTCAGGAAAGC
Probe (100 nM) 5-6FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA
Bovine RSV Ncap Fwd (1000 nM) 5-CAGTCAAGAATATTATGCTTGGTCATG
Rev (1000 nM) 5-CCTAACTTTTGTGCATATTCATAGACTTC
Probe (150 nM) 5-6FAM-CAACCTGTTCCATTTCTGCTTGTACGCTG-TAMRA
ovRPS15 Fwd (1000 nM) 5-CGAGATGGTGGGCAGCAT
Rev (1000 nM) 5-GCTTGATTTCCACCTGGTTGA
Probe (150 nM) 5-VIC-CCGGCGTCTACAACGGCAAGACC-TAMRA
hRibo18S Fwd (50 nM) 5-CGGCTACCACATCCAAGGAA
Rev (50 nM) 5-GCTGGAATTACCGCGGCT
Probe (200 nM) 5-VIC-TGCTGGCACCAGACTTGCCCTC-TAMRA
a6FAM or VIC, 5 fluorescent reporter dye; TAMRA, fluorescent quencher dye.
generated during qPCR of total RNA from the whole lung
homogenates in this study (30). For each animal, RNA
sample real-time target gene amplifications were normal-
ized to the geometric mean of two housekeeping genes,
hRibo18S and ovRPS15 (the latter sequence was kindly
provided by S. Limesand, University of Colorado Health
Sciences Center, Aurora, CO).
Morphometry
Gross lesions were assessed on the basis of a scoring
system in which multifocal to coalescing areas of plum-
red consolidation were expressed as a percentage of lung
area: 0, 0%; 1, 5%; 2, 5–20%; 3, 21–40%; 4, 41–60%;
and 5, 60%.
Neutrophil infiltration into bronchioles was assessed
by a pathologist (26). Briefly, low-magnification sites
(n  10) were randomly selected, a bronchiole from each
site was targeted, and the number of neutrophils within
the basement membrane and lumen were counted and val-
ues per section averaged.
Statistical analysis
In pretreatment of qPCR data, we found that the stan-
dard deviation of replicated measurements increased with
its respective mean. Thus all qPCR measurements were
log transformed in order to stabilize variance.
For each RNA sample, the arithmetic mean of log
transformations of all measurements of its housekeeper
genes (two genes) was used as a normalization factor.
This normalization factor was then subtracted from each
measurement of the target gene after being log trans-
formed. The result is the relative gene expression of each
target gene. This operation is equivalent to dividing raw
measurements of each target gene by the geometric
means of all measurements of its corresponding house-
keeper genes.
We used a standard two-sample t test to compare ex-
pression of the same target gene under different treatment
conditions. In the case of treatments with significantly
different variances, we compared means through a Welch
modified two-sample t test. Variances between different
treatments were compared through an F statistic.
We used a balanced two-way analysis of variance (seven
replications per treatment) to test for effect of treatments
on body temperature, but grouping for possible variability
due to day postinfection. Seven replications were randomly
chosen from treatments with more than seven replications.
Mean body temperature was calculated by taking the sum
of daily body temperatures for each animal during the
course of the infection and dividing by the days assessed.
Significant differences in body temperature means of dif-
ferent treatments was established through the least signifi-
cant difference (LSD) method.
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We used two-way analysis of variance to test the treat-
ments on scores for gross lesions and neutrophil infiltra-
tion. If significance was detected as a result of treatment
then post-hoc tests were applied to scientifically relevant
comparisons.
RESULTS
Clinical RSV infection
During the course of infection, all the RSV-infected
animals exhibited mild to moderate clinical signs includ-
ing increased body temperature, tachypnea, and cough,
whereas the control groups lacked clinical signs. No sig-
nificant difference between treatments was detected in
degree of clinical signs such as tachypnea, cough, ap-
petite, and clinical appearance (data not shown). RSV
treatment caused a significant increase in mean body tem-
perature during the course of infection compared with
sham inoculation with sterile media (C/RSV  C/Media;
p  0.001) (Fig. 1A). Pretreatment of sham-inoculated
groups caused no significant alteration in mean temper-
ature; however, rhVEGF pretreatment of RSV infection
increased mean body temperature compared with be-
tamethasone pretreatment (V/RSV  B/RSV; p  0.05),
RSV infection alone (V/RSV  C/RSV; p  0.05), and
rhVEGF pretreatment alone (V/RSV  V/Media; p 
0.001). The increased body temperature induced by
rhVEGF pretreatment in the RSV groups was not char-
acterized by extremely high values on any given day, but
rather by persistently elevated values throughout the
course of infection.
RSV lesions and replication
All RSV-infected groups exhibited the typical RSV-
induced gross lesions of plum to red consolidation,
whereas the group given media lacked lesions. Signifi-
cant difference in distribution and severity of gross le-
sions between treatment groups was not detected (Fig.
1B). Microscopically, whereas all RSV-infected groups
had typical RSV lesions (necrotizing bronchiolitis, ep-
ithelial syncytia, etc.), there was significant reduction in
neutrophilic inflammation within the RSV-infected bron-
chioles of rhVEGF-pretreated versus saline (p  0.07)
and betamethasone groups (p  0.05) (Fig. 1C).
qPCR analysis of whole lung homogenates detected a
significant reduction in RSV mRNA expression in the
rhVEGF pretreatment group compared with saline (p 
0.00001) and betamethasone (p  0.01) (Fig. 2A).
Analysis between mean body temperature during the
course of infection and levels of RSV replication by day
5 of infection demonstrated a strong correlation among
individual animals (p  0.06) and a group interaction
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(r  –0.88) can be seen in the group plot, demonstrating
the V/RSV group as having the higher body temperature
and lower viral replication than the other pretreatment
groups (Fig. 2B).
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Innate immune gene expression
Sheep -defensin-1 (SBD1) mRNA expression was in-
creased in rhVEGF versus saline or betamethasone pre-
treated, sham-infected groups (p  0.05) (Fig. 3A). Dur-
ing RSV infection, the saline pretreatment group had
increased SBD1 expression (C/RSV  C/Media; p 
0.1); however, rhVEGF pretreatment of RSV infection
suppressed SBD1 expression compared with either the
rhVEGF or RSV group control (V/RSV  V/Media or
C/RSV; p  0.05).
Surfactant protein D (SP-D) mRNA expression was
not significantly altered by pretreatments in the sterile
media controls (Fig. 3B). Independently, RSV infection
reduced SP-D mRNA expression (C/Media  C/RSV;
p  0.05). This reduction in SP-D mRNA expression by
RSV infection was mitigated to near control levels 
by rhVEGF and betamethasone pretreatment (C/RSV 
B/RSV or V/RSV; p  0.05).
SP-A expression, similar to SP-D expression, was sta-
tistically unaltered by pretreatment in the control groups
(Fig. 3C). RSV infection increased SP-A expression
192
FIG. 1. Clinical comparison of sham- and RSV-infected
neonatal lambs pretreated with saline, betamethasone, or
rhVEGF. (A) Mean body temperature. RSV infection overall
caused a significant increase in group mean body temperatures
(p  0.001). In RSV-infected lambs, rhVEGF pretreatment in-
creased mean body temperature compared with RSV infection
alone (C/RSV; p  0.05), betamethasone (B/RSV; p  0.05)
pretreatment or compared with rhVEGF pretreatment of con-
trols (7V/Media; p  0.001). (B) Gross lesions. No significant
alterations in gross lesions were detected. (C) Bronchiole in-
flammation. The number of neutrophils was reduced after
rhVEGF pretreatment compared with saline (V/RSV  C/RSV;
p  0.07) or betamethasone (V/RSV  B/RSV; p  0.05).
FIG. 2. RSV replication in neonatal lambs pretreated with
saline, betamethasone, or rhVEGF. (A) RSV mRNA expres-
sion. RSV mRNA expression (log10) was reduced in the
rhVEGF pretreatment group compared with saline (p 
0.00001) and betamethasone (p  0.01) pretreatment. (B) Body
temperature and RSV replication interaction. Among lambs
there was a trend toward reduced viral replication with higher
mean body temperature (p  0.06). This correlation (r  –0.88)
was distinct between the treatment groups V/RSV  103.7;
B/RSV  103.4; C/RSV  103.3).
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(C/RSV  C/Media; p  0.01) but pretreatment with
rhVEGF or betamethasone suppressed the RSV-induced
alteration (C/RSV  V/RSV or B/RSV; p  0.05)
DISCUSSION
The purpose of this study was to compare novel
(rhVEGF), traditional (betamethasone), or sham (sterile
medium) RDS therapy in a perinatal lamb model of RSV
infection. The rationale for “pretreatment” of rhVEGF
therapy was made on the presumption that rhVEGF could
be used for RDS therapy (and increased antiviral surfac-
tant proteins) and thereby would already be active in
high-risk infants that become exposed to RSV. Indeed,
rhVEGF pretreatment in this study mitigated several key
parameters of RSV infection.
All RSV-infected lambs had mild to moderate clinical
signs including increased body temperature, cough, and
tachypnea consistent with previous work in our laboratory
(23,25). Interestingly, clinical signs of RSV infection were
not significantly mitigated except for body temperatures.
In this particular animal model there is typically a tran-
sient, mild increase in body temperature on the first day
because of inoculum (RSV antigen) delivery followed by
another moderate increase on days 3–5 of infection corre-
sponding to pulmonary viral replication and activation of
the immune response. In this current study, rhVEGF pre-
treatment increased daily body temperature during the
course of infection, resulting in an increase in mean body
temperature. Interestingly, the rhVEGF pretreatment group
also had decreased RSV viral mRNA expression on day 5
of the experiment, representing the time of maximum vi-
ral replication in this model (23,25). The increased mean
body temperature in the rhVEGF pretreatment group likely
affected RSV replication as they were inversely correlated.
It is recognized that elevated body temperature is a by-
product of the innate immune system, often resulting from
cytokine (e.g., interleukin [IL]-1, IL-6, and tumor necro-
sis factor [TNF]-) expression (10). Increased temperature
can inhibit in vitro replication of some viruses including
influenza and feline immunodeficiency virus and temper-
ature regulation is in part the foundational precept of RSV
temperature-sensitive vaccines (2,7,34). The correlation of
increased body temperature during the course of disease
to decreased RSV replication is a novel finding for this
perinatal RSV model.
We speculate that at least three different mechanisms
may be involved in the sustained elevated body temper-
ature and reduced viral expression by rhVEGF pretreat-
ment. rhVEGF can interact with the endothelial VEGF
receptor and promote angiogenesis, a prominent compo-
nent of this process being enhanced vascular permeabil-
ity (11,12). This subtle (not detected clinically) vascular
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FIG. 3. Innate immune gene expression. (A) SBD1 mRNA
expression (log10). SBD1 expression in sham inoculates was in-
creased by rhVEGF relative to saline (p  0.05) or betametha-
sone (p  0.05) pretreatment, with similarly increased expres-
sion detected in RSV infection (C/RSV  C/Media; p  0.1).
Whereas rhVEGF pretreatment and RSV infection each in-
creased SBD1 expression (V/Media  C/Media, p  0.05;
C/RSV  C/Media, p  0.05), the combination of rhVEGF
pretreatment and RSV infection suppressed SBD1 expression
(V/Media vs. V/RSV, p  0.05; C/RSV vs. V/RSV, p  0.05).
(B) SP-D mRNA expression (log10). SP-D expression was not
significantly altered by pretreatment in sham-inoculated groups.
RSV infection (C/Media  C/RSV; p  0.05) reduced SP-D
expression, whereas pretreatment with rhVEGF and be-
tamethasone suppressed the RSV-induced alteration to near
control levels (C/RSV  V/RSV or B/RSV; p  0.05). (C) SP-
A mRNA expression (log10). SP-A expression was unaltered
by pretreatment in sham-inoculated groups. RSV infection in-
creased SP-A compared with sham-infected control (C/RSV 
C/Media; p  0.01) and this RSV-induced alteration was sup-
pressed by rhVEGF and betamethasone pretreatment (C/RSV 
V/RSV or B/RSV; p  0.05).
leakage could allow extravasation of antibodies or other
innate immune components (e.g., mannose-binding
protein) for antigen–antibody complex formation; an
important source of pyrogenicity in viral infection (
19). A second potential mechanism is related to the 
recruitment of monocytes and macrophages to sites of
VEGF expression/administration (3,27). Monocytes/
macrophages are important producers of pyrogenic cy-
tokines after phagocytosis of antigen (38). rhVEGF re-
cruitment of monocytes/macrophages to the lung could
contribute to enhanced opportunity for interaction with
virus from the inoculum (early infection) or infected
cells (mid to late infection) for cytokine production.
Last, although body temperature was correlated with
reduced viral inhibition, we cannot exclude the premise
that increased temperature and reduced RSV replica-
tion are both mediated as a direct result of some innate
mediator such as cytokine or cellular effects, such as
B cell proliferation seen in mice (13,28). Specifically,
alterations to -defensin and surfactant protein expres-
sion, which both have both antiviral and immunomod-
ulatory capacity, may have contributed to the reduced
RSV replication.
In this model of RSV disease, neutrophil inflammation
in bronchioles was reduced by rhVEGF pretreatment.
Neutrophilic exocytosis is a major cause of epithelial
damage and airway obstruction contributing to ventila-
tion compromise during RSV disease in children (37,42).
VEGF interaction with endothelium can regulate adhe-
sion molecule expression and even enhance neutrophil
emigration; however, in this case the reduced neutrophil
recruitment was likely due to diminished virus replica-
tion as this is a significant regulator of neutrophil emi-
gration in RSV disease (4,22,43).
Concerning innate immune gene mRNA levels, we
detected differential regulation of innate immune genes
by rhVEGF pretreatment and RSV infection. SBD1
mRNA expression was upregulated by rhVEGF pre-
treatment but not significantly altered during RSV in-
fection. This novel finding of rhVEGF-induced -de-
fensin mRNA expression is interesting and this
relationship may be defined in part as -defensins and
VEGF have been reported to synergize in the recruit-
ment of dendritic cells and in vasculogenesis of tumors
(9). The lack of SBD1 mRNA alteration during RSV
infection is consistent with investigation of laser cap-
ture microdissected bovine RSV-infected and nonin-
fected epithelia in which SBD1 mRNA expression was
not changed (20). Although SBD1 lacks NF-B regu-
latory elements, the regulatory pathway of SBD1 is not
yet fully defined (1).
In contrast to SBD1, surfactant proteins A and D were
not altered by rhVEGF pretreatment in control (non-
RSV-infected) lambs, but rhVEGF pretreatment (and be-
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tamethasone) did mitigate the magnitude of surfactant
protein mRNA alteration seen during RSV disease. Be-
tamethasone is a glucocorticoid therapeutically given to
perinatal infants to increase surfactant expression for pre-
vention of respiratory distress syndrome (5,38). VEGF
has been proposed as a novel therapeutic for lung matu-
ration and surfactant expression in place of glucocorti-
coids, which have potential adverse effects (8,21). Be-
cause rhVEGF and not betamethasone pretreatment
diminished select parameters of RSV disease (e.g., viral
replication and bronchiolar neutrophilic exudate), this
suggests that the mitigation of surfactant protein mRNA
alteration alone may not fully explain the RSV disease
mitigation and that other factors are more fundamental.
In summary, this study demonstrates that rhVEGF
pretreatment therapy can diminish select parameters of
RSV disease. Furthermore, rhVEGF pretreatment in-
teracts with RSV disease status to cause differential
regulation of innate immune gene expression. The role
of these innate immune gene alterations in relation to
rhVEGF therapy of RSV infection is not fully known.
These foundational results warrant further investigation
into the kinetics of perinatal VEGF therapy and RSV
disease.
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